Practical implication
Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.
The French National Agency for the Safety of Medicines and Health Products (ANSM) has published safety information concerning the Atellica CH Revised C-Reactive Protein (RCRP) diagnostic reagent. This information is crucial for laboratories conducting medical biology analyses.
What changed: The ANSM issued a safety action registration number R2625739 related to the Atellica CH Revised C-Reactive Protein (RCRP), applicable to laboratories performing medical biology analyses.
Why it matters: This alert is essential as it communicates safety concerns and operational changes required for the handling of the Atellica CH RCRP reagent, ensuring the safety and effectiveness of diagnoses made using it.
Practical implication: Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.
View original source
- Source: ANSM (France) - Safety information feed
- Published at source: 2026-09-07T00:00:00.000Z
- Discovered by monitor: 2026-09-07T21:36:51.064Z
Published from the regulator source ingestion pipeline after PV impact triage.
